Research Topics
Genomes and GenesSpecies | Richard J RobbinsSummaryAffiliation: Baylor College of Medicine Country: USA Publications
| Collaborators
|
Detail Information
Publications
Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanningRichard J Robbins
Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Endocrinol Metab 91:498-505. 2006..We hypothesized that the metabolic activity of metastatic lesions, as defined by retention of 2-[(18)F]fluoro-2-deoxyglucose (FDG), would correlate with prognosis...- Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxineRichard J Robbins
Endocrine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Thyroid 16:1121-30. 2006..Two patients had serious adverse events that were thought to be related to rhTSH. rhTSH elevates serum TSH and facilitates radioiodine uptake in patients who cannot produce endogenous TSH or who cannot tolerate hypothyroidism... - Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinomaRichard J Robbins
Endocrinology Service, Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Clin Endocrinol Metab 89:6010-6. 2004..We conclude that the location and volume of metastases influence basal Tg, but not its responsiveness to rhTSH, whereas the histological type of carcinoma influences both basal Tg and responsiveness to rhTSH... - Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawalR Michael Tuttle
Division of Endocrinology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
J Nucl Med 49:764-70. 2008..However, no published study has determined the effectiveness of rhTSH preparations on the important endpoint of disease recurrence... - A sequence-specific exopeptidase activity test (SSEAT) for "functional" biomarker discoveryJosep Villanueva
Protein Center, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Mol Cell Proteomics 7:509-18. 2008..The test all but eliminates reproducibility problems related to sample collection, storage, and handling as well as to possible variability in endogenous peptide precursor levels because of hemostatic alterations in cancer patients... - Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancerR Michael Tuttle
Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Nucl Med 47:1587-91. 2006.... - Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) softwareGeorge Sgouros
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
J Nucl Med 45:1366-72. 2004..This input has typically been obtained from SPECT and planar imaging studies. The objective was to implement and evaluate PET-based, patient-specific, 3D dosimetry for thyroid cancer patients... - A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablationRichard J Robbins
Endocrinology Service, Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Nucl Med 43:1482-8. 2002..During this same time period, other patients at our center were prepared for RRA by hormone withdrawal... - Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patientsDaniel A Pryma
Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
J Nucl Med 47:1260-6. 2006..However, there is limited information with regard to the true diagnostic accuracy and prognostic value of 18F-FDG PET in this disease... - Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and ageJosep Villanueva
Protein Center, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Mol Cell Proteomics 5:1840-52. 2006.... - Coming of age: recombinant human thyroid-stimulating hormone as a preparation for (131)i therapy in thyroid cancerRichard J Robbins
Memorial Sloan-Kettering Cancer Center, New York, New York
J Nucl Med 44:1069-71. 2003 - The value of positron emission tomography (PET) in the management of patients with thyroid cancerRichard J Robbins
Endocrine Division, Department of Medicine, The Methodist Hospital, Houston, TX 77030, USA
Best Pract Res Clin Endocrinol Metab 22:1047-59. 2008..The majority of the published studies to date have used 18F-fluoro-deoxyglucose (FDG) as the PET isotope, and unless specifically noted, all references to PET scanning will imply that this tracer has been used... - Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma?Richard J Robbins
Endocrinology Service, Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
J Clin Endocrinol Metab 87:3242-7. 2002..We conclude that the stimulated Tg alone is not sufficient by itself to screen unselected patients, but that it may be sufficient in low risk patients, especially those who have had a prior negative DxWBS... - Clinical review 156: Recombinant human thyrotropin and thyroid cancer managementRichard J Robbins
Endocrine Service, Division of General Medicine, Department of Medicine, and Medical Library-Nathan Cummings Center, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
J Clin Endocrinol Metab 88:1933-8. 2003 - The evolving role of (131)I for the treatment of differentiated thyroid carcinomaRichard J Robbins
Endocrine Service, Division of General Medicine, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Nucl Med 46:28S-37S. 2005..131)I will continue to be a major weapon in the fight against metastatic thyroid carcinoma. Its future role will be modified by expanding knowledge of its relative risks and benefits... - Hürthle cell carcinoma of the thyroid presenting as thyrotoxicosisHarsha Karanchi
Department of Medicine, The Methodist Hospital, Houston, Texas 77030, USA
Endocr Pract 18:e5-9. 2012..To report a case of hyperthyroidism associated with Hürthle cell carcinoma and to review the literature regarding this relationship... 
Correcting common errors in identifying cancer-specific serum peptide signaturesJosep Villanueva
Protein Center, Molecular Biology Program, Engineering Resource Laboratory, Department of Clinical Laboratories, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
J Proteome Res 4:1060-72. 2005..g., gender, age, genetics, environmental, dietary, and other factors) may now be addressed...- Expanding indications for recombinant human TSH in thyroid cancerBryan R Haugen
Thyroid 18:687-94. 2008 - Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinibDarren R Feldman
J Natl Cancer Inst 99:974-5; author reply 976-7. 2007 - Distilling cancer biomarkers from the serum peptidome: high technology reading of tea leaves or an insight to clinical systems biology?Richard J Robbins
J Clin Oncol 23:4835-7. 2005 - Statins sentence thyroid cancer cells to death rhoRichard J Robbins
J Clin Endocrinol Metab 88:3019-20. 2003 - Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trialAndrew R Hoffman
Veterans Affairs Palo Alto Health Care System and Stanford University, Palo Alto, California 94304, USA
J Clin Endocrinol Metab 89:2048-56. 2004..GH treatment was generally well tolerated. Subjects with AGHD should receive individualized GH therapy to maintain IGF-I between the mean value and +2 SD and improve body composition and cardiovascular risk factors...